Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Analysis summary4-Traders Strategies

Anaïs Lozach

 
 
share with twitter share with LinkedIn share with facebook
share via e-mail

The resistance should give in

Strategy published on 08/10/2017 | 14:33
long trade
Stop-loss triggered
Entry price : 135.05$ | Target : 141$ | Stop-loss : 132.9$ | Potential : 4.41%
Celgene Corporation is close to a major resistance level, whereby the breach of this level could be considered as a buy signal. This reflects our preferred scenario in light of the stock's current technical chart pattern.
Investors have an opportunity to buy the stock and target the $ 141.
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

Strengths
  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 61% by 2019.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The tendency within the weekly time frame is positive above the technical support level at 116.78 USD

Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at USD 137.74.
  • The stock is close to a major daily resistance at USD 137.84, which should be gotten rid of so as to gain new appreciation potential.
  • Based on current prices, the company has particularly high valuation levels.
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Company
Develops human pharmaceuticals and agrochemicalsCelgene Corp. is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.Its targeting... 
Financials ($)
Sales 2017 13 259 M
EBIT 2017 7 526 M
Net income 2017 4 419 M
Debt 2017 2 800 M
Yield 2017 -
P/E ratio 2017 22,60
P/E ratio 2018 17,46
EV / Sales 2017 7,74x
EV / Sales 2018 6,37x
Capitalization 99 867 M
Chart CELGENE CORPORATION
Duration : Period : Day
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Duration : Period : Week
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes